Will Rogers Phenomenon in Multiple Sclerosis

被引:80
作者
Sormani, Maria Pia [1 ,2 ]
Tintore, Mar [3 ]
Rovaris, Marco [1 ]
Rovira, Alex [4 ]
Vidal, Xavier [5 ]
Bruzzi, Paolo [6 ]
Filippi, Massimo [1 ]
Montalban, Xavier [3 ]
机构
[1] Ist Sci San Raffaele, Dept Neurol, Neuroimaging Res Unit, I-20132 Milan, Italy
[2] Univ Genoa, Dept Hlth Sci, DISSAL, Biostat Unit, I-16126 Genoa, Italy
[3] Vall Hebron Univ Hosp, Clin Neuroimmunol Unit, Barcelona, Spain
[4] Vall Hebron Univ Hosp, Magnet Resonance Unit, Barcelona, Spain
[5] Vall Hebron Univ Hosp, Clin Pharmacol Serv, Barcelona, Spain
[6] Natl Inst Canc Res, Dept Epidemiol & Prevent, Genoa, Italy
关键词
D O I
10.1002/ana.21464
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Using different criteria for classifying patients into various stages of a disease can modify the stage-specific prognosis, even though the overall disease course remains unchanged. This is known as the "Will Rogers phenomenon," precluding the use of historical controls for treatment trials. We assessed whether the Will Rogers phenomenon may affect multiple sclerosis (MS) prognosis when applying different diagnostic criteria. Methods: Patients with a clinically isolated syndrome (CIS) suggestive of MS were studied. After 1 year, each patient was classified as CIS or evolved to MS according to two diagnostic criteria (Poser and McDonald). The outcome for prognosis was the time to reach an Expanded Disability Status Scale score >= 3.0. Results: 309 patients were studied for a median period of 84 months. After 1 year, 16% of patients had MS according to Poser and 44% according to McDonald criteria. The probability to reach Expanded Disability Status Scale score >= 3.0 at median follow-up was 11% in CIS patients according to Poser and 7% according to McDonald criteria; it was 46% in MS patients according to Poser and 27% acccording to McDonald criteria. The group with a discordant diagnosis had a worse prognosis than that of CIS patients according to both criteria (p = 0.01), but better than that of MS patients according to both criteria (p = 0.01). Interpretation: The use of different diagnostic criteria may generate spurious improvements in the medium-term prognosis of MS. This calls for caution in using historical controls for MS trials.
引用
收藏
页码:428 / 433
页数:6
相关论文
共 24 条
[1]   Prostate cancer and the Will Rogers phenomenon [J].
Albertsen, PC ;
Hanley, JA ;
Barrows, GH ;
Penson, DF ;
Kowalczyk, PDH ;
Sanders, MM ;
Fine, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1248-1253
[2]   CEREBROSPINAL-FLUID IN THE DIAGNOSIS OF MULTIPLE-SCLEROSIS - A CONSENSUS REPORT [J].
ANDERSSON, M ;
ALVAREZCERMENO, J ;
BERNARDI, G ;
COGATO, I ;
FREDMAN, P ;
FREDERIKSEN, J ;
FREDRIKSON, S ;
GALLO, P ;
GRIMALDI, LM ;
GRONNING, M ;
KEIR, G ;
LAMERS, K ;
LINK, H ;
MAGALHAES, A ;
MASSARO, AR ;
OHMAN, S ;
REIBER, H ;
RONNBACK, L ;
SCHLUEP, M ;
SCHULLER, E ;
SINDIC, CJM ;
THOMPSON, EJ ;
TROJANO, M ;
WURSTER, U .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1994, 57 (08) :897-902
[3]   Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer [J].
Basu, Sandip ;
Alavi, Abass .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (01) :1-4
[4]  
D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO
[5]  
2-B
[6]   Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].
Ebers, GC ;
Rice, G ;
Lesaux, J ;
Paty, D ;
Oger, J ;
Li, DKB ;
Beall, S ;
Devonshire, V ;
Hashimoto, S ;
Hooge, J ;
Kastrukoff, L ;
Krieger, C ;
Mezei, M ;
Seland, P ;
Vorobeychi, G ;
Morrison, W ;
Nelson, J ;
Freedman, MS ;
Chrisie, S ;
Nelson, R ;
Rabinovitch, H ;
Freedman, C ;
Hartung, HP ;
Rieckmann, P ;
Archelos, J ;
Jung, S ;
Weilbach, F ;
Flachenecke, P ;
Sauer, J ;
Hommes, O ;
Jongen, P ;
Brouwer, S ;
McLeod, J ;
Pollard, J ;
Ng, R ;
Sandberg-Wollheim, M ;
Källén, K ;
Nilsson, P ;
Ekberg, R ;
Lundgren, A ;
Jadbäck, G ;
Wikström, J ;
Multanen, J ;
Valjakka, M ;
Carton, H ;
Lissoir, F ;
Declerq, I ;
Vieren, M ;
Peeters, E ;
Dubois, B .
LANCET, 1998, 352 (9139) :1498-1504
[7]   THE ROGERS,WILL PHENOMENON - STAGE MIGRATION AND NEW DIAGNOSTIC-TECHNIQUES AS A SOURCE OF MISLEADING STATISTICS FOR SURVIVAL IN CANCER [J].
FEINSTEIN, AR ;
SOSIN, DM ;
WELLS, CK .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (25) :1604-1608
[8]   Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis:: a 3-year follow-up analysis of the BENEFIT study [J].
Kappos, Ludwig ;
Freedman, Mark S. ;
Polman, Chris H. ;
Edan, Gilles ;
Hartung, Hans-Peter ;
Miller, David H. ;
Montalban, Xavier ;
Barkhof, Frederik ;
Radu, Ernst-Wilheim ;
Bauer, Lars ;
Dahms, Susanne ;
Lanius, Vivian ;
Pohl, Christoph ;
Sandbrink, Rupert .
LANCET, 2007, 370 (9585) :389-397
[9]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[10]   Placebo-controlled clinical trials in multiple sclerosis: Ethical considerations [J].
Lublin, FD ;
Reingold, SC .
ANNALS OF NEUROLOGY, 2001, 49 (05) :677-681